Precipio Inc (PRPO)
NASDAQ:PRPO
Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$23.09
$0.30(5.08%)
At close: 4:00 PM EST
$23.09
$0.30(5.08%)
Day’s Range― - ―
52-Week Range$10.52 - $33.63
Previous CloseN/A
Volume11.00
Average Volume (3M)19.92K
Market Cap
$40.13M
Enterprise Value$40.85M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$3.49M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding1,787,372
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit3.62
Enterprise Value/Ebitda47.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Stronger Cash GenerationConsistent top-line growth alongside positive operating and free cash flow indicates Precipio is converting higher test volumes into cash. Durable cash generation reduces reliance on external financing, supports reinvestment in commercial scale-up and operations, and underpins sustainable execution of growth plans.
Lab Capacity And Operational ScalabilitySubstantial unused lab capacity implies meaningful room to grow revenue without heavy immediate capital spending. That structural scalability can deliver operating leverage and margin expansion as commercial conversion accelerates, improving long-term unit economics and ROI on prior lab investments.
Manageable Leverage And Tangible Balance-sheet BaseLow relative leverage and a tangible asset base provide financial flexibility typical of a small-cap diagnostics operator. This cushioning reduces refinancing risk, supports selective commercial investment and hiring, and helps the company absorb episodic reimbursement or timing shocks while executing its growth plan.
Bears Say
Regulatory/reimbursement Risk From CMS Fee ChangesReimbursement cuts are structural risks for lab-based businesses because they directly compress revenue and gross margins. An 8% CMS cut caused a meaningful write-down this quarter; further fee-schedule adjustments or payor rate pressure would continue to erode realized pricing and require either higher volumes or cost reductions to offset.
Inconsistent Profitability And Margin VolatilityWhile margins and EBITDA improved versus earlier years, profitability is not yet consistent. Periodic swings to negative EBITDA and a lingering TTM net loss constrain reinvestment capacity and increase execution risk; sustained margin recovery is needed to firmly shift the company from fragile break-even to durable profitability.
Onboarding And Operational Execution FrictionsConversion of a sizable commercial pipeline depends on operational execution. Persistent onboarding delays raise the risk that booked opportunities take longer to materialize, which can push out expected revenue, increase onboarding costs, and limit the near-term realization of scale benefits despite a healthy pipeline.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $10.52 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $40.13M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Aug 04, 2026 which is in 44 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on May 14, 2026. The company reported -$0.809 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.809.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,787,372 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.809 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.951%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
-6.73%
Trailing 12-Months
Asset Growth
16.97%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
PRPO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong underlying trends and short-term headwinds. Positives include >30% YoY revenue growth, a growing pathology business, a $10M annualized commercial pipeline and positive operating cash flow. Near-term negatives included an 8% CMS reimbursement cut causing a ~$0.5M write-down, a QoQ gross margin decline (47% to 40%), and an adjusted EBITDA decline to -$200k driven by timing and investment-related factors. Management framed most negatives as one-time or investment-driven and emphasized scalability, available lab capacity, and commercial momentum, with expectations for margin recovery as product revenue scales.View all PRPO earnings summariesTechnical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
10.83% Insiders
2.28% Mutual Funds
1.91% Other Institutional Investors
82.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---